Varicella-Zoster Ge/As01b/Pf
Brand name: Shingrix
Rank #36 of 500 drugs by total cost
$514.4M
Total Cost
2,419,884
Total Claims
$514.4M
Total Cost
18,985
Prescribers
$213
Cost per Claim
1,811,736
Beneficiaries
2,432,203
30-Day Fills
$27K
Avg Cost/Provider
127
Avg Claims/Provider
About Varicella-Zoster Ge/As01b/Pf
Varicella-Zoster Ge/As01b/Pf (sold as Shingrix) was prescribed 2,419,884 times by 18,985 Medicare Part D providers in 2023, costing the program $514.4M. At $213 per claim, this is a moderately priced medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 33 | Insulin Degludec (Tresiba Flextouch U-100) | $567.8M | 597,178 |
| 34 | Valbenazine Tosylate (Ingrezza) | $553.8M | 73,914 |
| 35 | Fluticasone Propion/Salmeterol (Advair Diskus) | $523.2M | 1,289,942 |
| 36 | Varicella-Zoster Ge/As01b/Pf (Shingrix) | $514.4M | 2,419,884 |
| 37 | Tafamidis (Vyndamax) | $511.1M | 20,589 |
| 38 | Fluticasone/Vilanterol (Breo Ellipta) | $493.0M | 909,837 |
| 39 | Tiotropium Bromide (Spiriva Handihaler) | $478.1M | 673,800 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology